Novo Nordisk 2006 sales grew by 15% driven by modern insulins. Lars Rebien Sørensen, president and CEO, said: “We are very pleased with the results. Sales of our key products went well in all major markets, and we continue to see productivity improvements in Product Supply. This allows us to invest more in both R&D and sales and marketing, and we remain confident that also in 2007 we will be able to deliver a solid financial performance."
Attachments
